Evaluation of Chagas Blood Screening and Confirmatory Assays

Not Applicable

Completed

• Conditions: Healthy
• Interventions: Device: ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay

• Registration Number: NCT00718042
• Lead Sponsor: Abbott Diagnostics Division

Brief Summary

Protocol designed to test blood samples from blood donors of whole blood and blood components using a new investigational screening test (PRISM Chagas) that detects antibody to T. cruzi (Chagas infection). Results will be compared to the current T. cruzi antibody screening assay. Specimens positive with the screening assay will be further tested with a new investigational Chagas confirmatory assay \[Enzyme Strip Assay (ESA) Chagas\]. Additional specimens collected under separate protocols or sourced from suppliers will also be provided to the clinical sites for testing with PRISM Chagas assay and ESA Chagas.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-06
• Study First Submitted: 2008-07-16
• Study First Submitted QC: 2008-07-16
• Study First Posted: 2008-07-18
• Primary Completion: 2009-07
• Study Completion: 2009-09
• Results First Submitted: 2011-12-16
• Results First Submitted QC: 2011-12-16
• Results First Posted: 2012-01-23
• Status Verified: 2012-02
• Last Update Submitted: 2012-03-02
• Last Update Posted: 2012-03-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 41862

Inclusion Criteria

• Healthy donors that have consented to participate in study

Exclusion Criteria

• N/A

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
1	ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay	All subjects will have their blood tested by the investigational Chagas screening assay.
2	ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay	Testing of blood donor samples with the investigational Chagas screening assay. Samples that test positive will be also tested with the Chagas confirmatory assay.

Primary Outcome Measures

Name	Time	Method
PRISM Chagas Specificity	6 months	Total of 16,249 serum and plasma blood donor specimens tested with PRISM Chagas assay during design validation phase. Repeatedly reactive specimens were tested further with a supplemental assay \[radioimmune precipitation assay (RIPA)\].
PRISM Chagas Sensitivity	6 months	Specimens from subjects known to be T cruzi parasite positive were tested with PRISM Chagas assay.
ESA Chagas Specificity	3 months	Preselected US blood donor specimens (330) presumed T cruzi antibody negative negative that were tested only with the investigational ESA Chagas.
ESA Chagas Sensitivity	3 months	Specimens from individuals known to be T cruzi parasite positive were tested with ESA Chagas assay.

Secondary Outcome Measures

Name	Time	Method
PRISM Chagas Reactivity Serology Positive Specimens	4 months	Total of 85 specimens from subjects from South America known to be positive for T cruzi antibodies and 202 US blood donor specimens that were repeatedly reactive on a licensed test for antibodies to T cruzi were tested with the PRISM Chagas assay and supplemental testing (RIPA).
PRISM Chagas Reactivity in Chagas Endemic Population	2 months	Population of specimen collected in Chagas endemic area in South/Central America (524) were tested to demonstrate reactivity with the PRISM Chagas assay in a population with a 5% or greater prevalence of infection with T cruzi antibody. specimens tested with PRISM Chagas assay and licensed test for T cruzi antibody and if repeatedly reactive with either assay the specimens were tested with supplemental assay (RIPA). Data presented with PRISM Chagas and RIPA results.
ESA Chagas Testing of US Blood Donor Specimens Repeatedly Reactive by ABBOTT PRISM Chagas.	15 months	A total of 41,760 US blood donor specimens were tested by ABBOTT PRISM Chagas. Of these specimens, 58 out of 79 specimens were T cruzi antibody repeatedly reactive by ABBOTT PRISM Chagas (26 from 16,249 donor specimens tested in design validation phase and 32 from 25,511 specimens from the Chagas extended evaluation). Donor specimens that were repeatedly reactive with the licensed T cruzi antibody assay, but PRISM Chagas nonreactive (6) and specimens PRISM Chagas grayzone negative (15) were excluded from this analysis.
ESA Chagas Sensitivity in Serologically Positive Non-US Specimens	3 months	ESA Chagas Sensitivity in a non-US population was determined for the 85 out of the total 287 serologically positive specimens (202 US Serology Positive specimens were excluded). These specimens were collected from individuals positive for T cruzi antibodies based on 2 different serologic tests for antibodies to T cruzi in Argentina and were tested with ESA Chagas.
ESA Chagas Testing in Chagas Endemic Population	2 months	Specimen collected in Chagas endemic areas in South or Central America (524) tested with ESA Chagas and licensed test for T cruzi antibody. Specimens repeatedly reactive with either screening assay and/or ESA Chagas positive were tested with supplemental assay (RIPA). Presentation of ESA Chagas results for 132 specimens from a Chagas endemic population that were RIPA positive.

Trial Locations

Locations (7)

BloodNet USA; 🇺🇸 Lakeland, Florida, United States

Florida Blood Services; 🇺🇸 St. Petersburg, Florida, United States

Rhode Island Blood Center; 🇺🇸 Providence, Rhode Island, United States

LifeSource Blood Center; 🇺🇸 Glenview, Illinois, United States

American Red Cross Charlotte NTL; 🇺🇸 Charlotte, North Carolina, United States

South Texas Blood and Tissue Center; 🇺🇸 San Antonio, Texas, United States

American Red Cross; 🇺🇸 Portland, Oregon, United States